HealthDay News — Low-dose aspirin does not protect against cognitive decline, according to a review published April 20 in the Journal of the American Geriatrics Society.
Nicola Veronese, MD, from the Italian Research Council in Padova, and colleagues conducted a systematic literature review to identify observational and interventional studies that investigated low-dose aspirin and the incidence of dementia and cognitive impairment.
The researchers identified 8 studies (36,196 participants). Over a median of 6 years of follow-up, chronic use of low-dose aspirin was not associated with onset of dementia or cognitive impairment (5 studies; 26,159 participants; odds ratio, 0.82; 95% confidence interval, 0.55 to 1.22; P=0.33), after adjusting for a median of 3 potential confounders. In 3 randomized controlled trials (10,037 participants; median follow-up, 5 years), the use of low-dose aspirin in individuals without dementia was not associated with significantly better global cognition (standardized mean difference, 0.005; 95% confidence interval, −0.04 to 0.05; P=0.84).
“This review found no evidence that low-dose aspirin buffers against cognitive decline or dementia or improves cognitive test scores in randomized controlled trials,” the authors write.